Mitochondrial quality control in health and in Parkinson's disease

MA Eldeeb, RA Thomas, MA Ragheb… - Physiological …, 2022 - journals.physiology.org
As a central hub for cellular metabolism and intracellular signaling, the mitochondrion is a
pivotal organelle, dysfunction of which has been linked to several human diseases including …

[HTML][HTML] iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders

H Okano, S Morimoto - Cell Stem Cell, 2022 - cell.com
It has been 15 years since the birth of human induced pluripotent stem cell (iPSC)
technology in 2007, and the scope of its application has been expanding. In addition to the …

Mitochondrial dysfunction in Parkinson's disease: from mechanistic insights to therapy

XY Gao, T Yang, Y Gu, XH Sun - Frontiers in aging neuroscience, 2022 - frontiersin.org
Parkinson's disease (PD) is one of the most common neurodegenerative movement
disorders worldwide. There are currently no cures or preventative treatments for PD …

PINK1 and Parkin regulate IP3R-mediated ER calcium release

SJ Ham, H Yoo, D Woo, DH Lee, KS Park… - Nature …, 2023 - nature.com
Although defects in intracellular calcium homeostasis are known to play a role in the
pathogenesis of Parkinson's disease (PD), the underlying molecular mechanisms remain …

Targeting mitochondrial impairment in Parkinson's disease: challenges and opportunities

J Prasuhn, RL Davis, KR Kumar - Frontiers in cell and developmental …, 2021 - frontiersin.org
The underlying pathophysiology of Parkinson's disease is complex, but mitochondrial
dysfunction has an established and prominent role. This is supported by an already large …

Mitophagy and reactive oxygen species interplay in Parkinson's disease

B Xiao, J Kuruvilla, EK Tan - npj Parkinson's Disease, 2022 - nature.com
Mitophagy impairment and oxidative stress are cardinal pathological hallmarks in
Parkinson's disease (PD), a common age-related neurodegenerative condition. The specific …

A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson's disease: beneficial or detrimental effects

M Alrouji, HM Al-Kuraishy, AI Al-Gareeb, HM Saad… - …, 2023 - Springer
Parkinson's disease (PD) is an advanced neurodegenerative disease (NDD) caused by the
degeneration of dopaminergic neurons (DNs) in the substantia nigra (SN). As PD is an age …

Animal models of neurodegenerative disease: Recent advances in fly highlight innovative approaches to drug discovery

JA Tello, HE Williams, RM Eppler… - Frontiers in molecular …, 2022 - frontiersin.org
Neurodegenerative diseases represent a formidable challenge to global health. As
advances in other areas of medicine grant healthy living into later decades of life, aging …

Disruption of mitochondrial homeostasis: The role of PINK1 in Parkinson's disease

M Vizziello, L Borellini, G Franco, G Ardolino - Cells, 2021 - mdpi.com
The progressive reduction of the dopaminergic neurons of the substantia nigra is the
fundamental process underlying Parkinson's disease (PD), while the mechanism of …

Genome editing in iPSC-based neural systems: from disease models to future therapeutic strategies

A McTague, G Rossignoli, A Ferrini, S Barral… - Frontiers in Genome …, 2021 - frontiersin.org
Therapeutic advances for neurological disorders are challenging due to limited accessibility
of the human central nervous system and incomplete understanding of disease …